Beta-herpesvirus challenges in the transplant recipient.
Cytomegalovirus (CMV) has major consequences after allogeneic stem cell and solid organ transplantation. CMV may cause significant morbidity and mortality, and monitoring to detect reactivation to reduce disease or management of end organ disease is associated with increased resource utilization. Two other members of the beta-herpesvirus family, human herpesvirus (HHV) type 6 and HHV-7, are increasingly recognized as important pathogens in transplant recipients, either by direct infection (e.g., encephalitis, hepatitis, or pneumonitis) or via interaction with CMV. In addition to direct effects of CMV infection, such indirect effects as an increased risk for bacterial and fungal infections or impaired graft acceptance and function are important research topics. Diagnosis and treatment of CMV infection is currently more advanced than for HHV-6 and HHV-7.
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D018141:Betaherpesvirinae; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006566:Herpesviridae Infections / Q000188:drug therapy*; D015654:Herpesvirus 6, Human; D016199:Herpesvirus 7, Human; D006801:Humans; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000188:drug therapy*; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000998:Antiviral Agents; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir